Development of New Therapeutic Strategies in Gynecological Cancers in Iran by Utilizing Xenograft Model of Ovarian Adenocarcinoma
-
Zohreh Mazaheri
,
Samad Muhammadnejad
,
Ahad Muhammadnejad
,
Moein Zargarzadeh
,
Maryam Haghighi
,
Mohammad Ali Oghabian
,
Farrokh Tirgari
,
Saeid Amanpour
Abstract
Objective: To evaluate the potentiality of OVCAR–3 cell line of ovarian adenocarcinoma as a xenograft model for ovarian adenocarcinoma in nude mice.
Materials and methods: The cell line isolated from advanced human ovarian adenocarcinoma, were inoculated to eight nude mice and two months later. Established tumors were transferred to pathology laboratory to be prepared by H&E staining and immunohistochemical staining with CA125 antibody.
Results: Study of H&E slides showed advanced adenocarcinoma. The CA125 Tumor marker was also positive in tumoral tissue.
Conclusion: Established tumors showed excellently the characteristics of ovarian adenocarcinoma. This model can be used to evaluate new treatment strategies.
American Cancer Society. Cancer Prevention & Early Detection Facts & Figures 2009. Atlanta, Ga: American Cancer Society; 2009.
Kumar R, Abbas A, Fausto A, Aster D. Robbins and Cotran Pathologic Basis of Disease, Saunders. 8th ed. 2010.
Fauci. A, Braunwald. E, Kasper. L, Hauser. J. Harrison's Principles of Internal Medicine. McGraw– Hill Professional. 17th ed. 2008.
Jeffrey H. Silber, Paul R. Rosenbaum, Daniel Polsky, Richard N. Ross, Orit Even–Shoshan, J. Sanford Schwartz, Katrina A. Armstrong KA, et al. Does Ovarian Cancer Treatment and Survival Differ by the Specialty Providing Chemotherapy? Journal of Clinical Oncology 2007; 25: 1169–75.
Arab M, Khayamzadeh M, Mohit M, Hosseini M, Anbiaee R, Tabatabaeefar M, et al. Survival of ovarian cancer in Iran: 2000–2004. Asian Pac J Cancer Prev (B) 2009; 10: 555–8.
Arab M, Khayamzadeh M, Tehranian A, Tabatabaeefar M, Hosseini M, Anbiaee R, et al. Incidence rate of ovarian cancer in Iran in comparison with developed countries. Indian J Cancer 2010; 47: 322–7.
Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, Whang–Peng J, Rogan AM, Green WR, Ozols RF. Characterization of a human ovarian carcinoma cell line (NIH: OVCAR–3) with androgen and estrogen receptors. Cancer Res 1983; 43: 5379–89.
Hamilton TC, Young RC, Louie KG, Behrens BC, McKoy WM, Grotzinger KR, et al. Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Cancer Res 1984; 44: 5286–90.
Rogan AM, Hamilton TC, Young RC, Klecker RW Jr, Ozols RF. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 1984; 224: 994–6.
Green JA, Vistica DT, Young RC, Hamilton TC, Rogan AM, Ozols RF. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res 1984; 44: 5427–31.
Go Wf. B.A, Hermanto U, Rumbaughl J,Blake J, Bamberg M, Hasan T. Photoimmunotherapy and biodistribution with an OC125–chiorin immunoconjugate in an in vivo murine ovarian cancer model. Br. J. Cancer 1994; 70: 474– 80.
Duska LR, Hamblin MR, Bamberg MP, Hasan T. Biodistribution of charged F(ab')2 photoimmunoconjugates in a xenograft model of ovarian cancer. Br J Cancer 1997; 75: 837–44.
| Files | ||
| Issue | Vol 4, No 3 (September 2010) | |
| Section | Original Articles | |
| Keywords | ||
| Gynecological cancers Xenograft model Ovarian adenocarcinoma | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
